Detail akcie REGENXBIO online

Business Summary: REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Regenxbio Inc revenues increased from $62.1M to $140.1M. Net loss decreased 28% to $126.7M. Revenues reflect License and royalty revenue increase from $62.1M to $129.1M. Lower net loss reflects Impairment of long-lived assets decrease from $2.1M (expense) to $0K, Research and development decrease of 12% to $12.2M (expense), General and administrative decrease of 7% to $14M (expense).